MESO News & Events

Latest data shows the largest indicative borrow rate increases among liquid option names include: Humacyte (HUMA) 16.96% +1.30, Infosys (INFY) 14.10% +1.29, Defiance 1.75x MSTR ETF (MSTX) 27.68% +1.03, Yellowstone Midco Holdings Ii, Llc (YSS) 5.98% +0.78, Mesoblast (MESO) 9.20% +0.53, Navient (NAVI) 0.94% +0.53, Equinor (EQNR) 1.81% +0.51, Rumble (RUM) 7.11% +0.49, Lucid Group (LCID) 27.88% +0.35, and Palladyne AI Corp (PDYN) 16.25% +0.33.

Mesoblast "announced that it has acquired an exclusive worldwide license to a patented chimeric antigen receptor - CAR - technology platform for precision-enhanced augmentation of therapeutic mesenchymal lineage stromal cell products. Mesoblast plans to incorporate the engineered CARs to further boost effectiveness of Mesoblast's products, with the goal of enhancing the target specificity and augmenting inherent properties of immunomodulation and tissue regeneration. Mesoblast's MSC technology platforms, including the first and only FDA-approved MSC product in the U.S., are designed for the treatment of tissue-specific inflammatory diseases due to their inherent homing capabilities and immunomodulatory properties. The aim of genetically engineering CAR constructs into MSCs is to substantially enhance targeted homing to inflamed tissue resulting in greater potency."

Mesoblast announced that the FDA has granted investigational new drug clearance to directly proceed for a registrational clinical trial evaluating Ryoncil in Duchenne muscular dystrophy, which affects approximately 15,000 children in the U.S.

Mesoblast announced Ryoncil net sales were $30.3M for the quarter ended March 31. Strong sales in February and March offset holiday seasonality in January. Revenue generated during this first year of Ryoncil launch approaches $100M.